10-Q: BioAtla Reports Q3 2025 Loss, Faces Going Concern Doubt

BioAtla, a clinical-stage biopharmaceutical company, reported a net loss of $15.8 million for Q3 2025 and $49.8 million for the nine months ended September 30, 2025, with management expressing substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $15.8 million for the three months ended September 30, 2025, compared to $10.6 million for the same period in 2024.
• Reported a net loss of $49.8 million for the nine months ended September 30, 2025, compared to $54.9 million for the same period in 2024.
• Cash and cash equivalents significantly decreased to $8.3 million as of September 30, 2025, from $49.0 million at December 31, 2024.
• Accumulated deficit increased to $535.9 million as of September 30, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the financial statements' issuance date.
• The company implemented a corporate restructuring in March 2025, including a 30% workforce reduction, and reduced its lease footprint in June 2025 to lower costs.
• No collaboration revenue was recognized for the three and nine months ended September 30, 2025, compared to $11.0 million in the prior year periods.
• Research and development expenses decreased to $9.5 million for Q3 2025 and $35.6 million for the nine months ended September 30, 2025, primarily due to lower enrollment and completion of Phase 2 trials for certain programs.
• General and administrative expenses decreased to $4.3 million for Q3 2025 and $14.5 million for the nine months ended September 30, 2025.
• The company received a $2 million milestone payment in November 2025 under the Context License Agreement.
• BioAtla is not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements, but was granted an extension by the Nasdaq Listing Qualifications Panel to regain compliance by December 31, 2025 (equity) and February 2, 2026 (bid price).

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to severe cash depletion, negative stockholders' equity, an explicit going concern warning, Nasdaq listing non-compliance, and a complete absence of collaboration revenue in the current period. While cost-cutting measures and a recent milestone payment offer minor positives, they are overshadowed by the significant financial distress and operational risks.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $49.8 million from $54.9 million in the prior year.
• Net cash used in operating activities for the nine months ended September 30, 2025, decreased to $40.3 million from $55.2 million in the prior year, indicating reduced cash burn.
• Research and development expenses decreased by $15.9 million for the nine months ended September 30, 2025, due to lower program development costs and workforce reduction.
• General and administrative expenses decreased by $2.8 million for the nine months ended September 30, 2025, due to cost-saving measures.
• A corporate restructuring in March 2025, including a 30% workforce reduction, and a reduction in lease footprint in June 2025, are expected to lower costs and extend cash runway.
• Received a $2 million milestone payment in November 2025 under the Context License Agreement, indicating progress in a partnered program.
• Ozuriftamab vedotin (BA3021) received Fast Track designation from the FDA in July 2024 for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Negatives

• Cash and cash equivalents significantly declined to $8.3 million as of September 30, 2025, from $49.0 million at December 31, 2024.
• Total stockholders' equity shifted to a deficit of $31.2 million as of September 30, 2025, from a positive $14.3 million at December 31, 2024.
• Accumulated deficit increased to $535.9 million as of September 30, 2025.
• No collaboration or other revenue was recognized for the three and nine months ended September 30, 2025, a significant drop from $11.0 million in the prior year periods.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year.
• Current cash and cash equivalents are estimated to be insufficient to fund operations for a period of at least twelve months from the report issuance date.
• The company is not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements and received a delist determination, although an extension was granted with conditions.
• Incurred a loss on warrant liability of $2.1 million for the three months ended September 30, 2025, and $0.5 million for the nine months ended September 30, 2025.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, with a history of significant losses and expected continued losses.
• Substantial additional capital is required to finance operations; failure to raise capital could force delays, reductions, or elimination of research and drug development programs or commercialization efforts.
• Product candidates may fail in development or suffer delays that adversely affect their commercial viability.
• The company is substantially dependent on the success of its patented CAB technology platform.
• Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials, and clinical trial results may not satisfy regulatory requirements.
• Resources may be expended on particular product candidates, failing to capitalize on potentially more profitable or successful ones.
• The market may not be receptive to product candidates due to their novel therapeutic modality, potentially limiting future revenue from sales or licensing.
• Preliminary, preplanned interim, and topline data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization.
• Significant competition from entities developing product candidates for cancer, including novel treatments and technology platforms.
• Non-compliance with Nasdaq's continued listing requirements could lead to delisting, affecting stock price and liquidity.
• Inability to obtain U.S. or foreign regulatory approval would prevent commercialization of product candidates.
• Seeking accelerated approval pathways, if available, may not be successful, requiring additional preclinical studies or clinical trials.
• Even with Fast Track designation, development or regulatory review may not be faster, and approval is not guaranteed.
• Ongoing regulatory obligations and review post-approval could result in significant additional expense, labeling restrictions, or market withdrawal.
• Substantial uncertainty regarding new Administration's initiatives and their impact on the FDA and other government agencies, potentially delaying development and approval.
• Failure to attract and retain qualified senior management and key scientific personnel could materially and adversely affect the business.
• Inability to establish sales, marketing, and distribution capabilities could prevent effective commercialization.
• Difficulties in managing organizational growth could hinder successful implementation of plans and strategies.
• Employees and independent contractors may engage in misconduct or improper activities, leading to significant liabilities and reputational harm.
• Dependence on information technology systems and third-party providers, vulnerable to failures, security breaches, and AI-related risks.
• Uncertainties regarding Chinese laws, trade wars, and political unrest could adversely affect research and development activities in China.
• Concentration of operations in two locations (San Diego, China) makes the company vulnerable to natural disasters or other disruptions.
• Economic, political, regulatory, and other risks associated with conducting business internationally.
• Health epidemics and outbreaks could significantly disrupt preclinical studies, patient enrollment in clinical trials, or delay regulatory approvals.
• Failure to enter into or maintain successful collaborations with third parties could limit market potential.
• Inability to obtain, maintain, and protect intellectual property rights, or if the scope of protection is insufficient, could allow competitors to develop similar products.
• Intellectual property rights of third parties could prevent or delay drug discovery and development, requiring costly litigation or licenses.
• Future issuance of equity or convertible debt securities will dilute share capital.
• Principal stockholders and management own a significant percentage of stock, potentially exerting control that conflicts with other stockholders' interests.
• Sales of a substantial number of shares could cause stock price to fall.
• Lack of research or adverse reports from securities analysts could cause stock price and trading volume to decline.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Ability to attract and retain qualified board members may be impacted by new diversity quota laws.
• Significant costs and management time devoted to public company compliance, and potential impairment of financial statements if internal controls fail.
• No anticipated cash dividends, so investment return depends on stock price appreciation.
• Potential for securities litigation, which is expensive and distracting.
• Designation of Delaware courts as exclusive forum for certain actions could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects to continue incurring significant operating expenses and losses for the foreseeable future, primarily due to research and development costs for product candidates. While near-term R&D expenses are expected to decrease as Phase 2 trials complete, long-term expenses are projected to increase substantially with further clinical development and potential commercialization. The company will require substantial additional capital, planning to finance operations through equity or debt financings, collaborations, or other arrangements. The timing and amount of future funding depend on various factors, including clinical trial progress and regulatory approvals. The company cannot assure profitability or positive cash flow from operations.

Management Comments

• We have incurred significant losses to date. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current and future product candidates.
• We do not expect to generate meaningful revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating expenses for the foreseeable future due to the cost of research and development.
• We expect research and development expenses to decrease in the near term as we complete our Phase 2 trials for certain indications.
• Over the long-term, we expect our expenses to increase substantially in connection with the development of our clinical programs beyond our existing Phase 1 and Phase 2 clinical trials and through the commercialization of our product candidates.
• As a result, we will require substantial additional capital to develop and commercialize our product candidates and fund operations for the foreseeable future.
• Based on our current operating plan, and along with our history of operating losses, our current cash and cash equivalents may not be sufficient to fund our ongoing operations for a period of at least twelve months from the date the financial statements included in this report are issued, and these circumstances raise substantial doubt about our ability to continue as a going concern.
• We believe that data from our ongoing clinical trials will enable us to raise additional capital which will address this doubt and enable us to continue as a going concern.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous multinational and specialized companies developing cancer treatments. BioAtla's conditionally active biologics (CABs) represent a novel therapeutic approach targeting tumor microenvironments. The industry faces significant regulatory scrutiny, particularly regarding clinical trial results and pricing, as evidenced by initiatives like Project Optimus and the Inflation Reduction Act. The increasing adoption of AI tools also introduces new risks and potential for accelerated development. Geopolitical tensions and trade disputes, especially with China where BioAtla conducts R&D, add further complexity and risk to international operations and supply chains. The company operates within a challenging environment characterized by high development costs, long approval timelines, and intense competition for capital and talent.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.
• The company's focus on conditionally active biologics (CABs) for solid tumor cancer positions it in a competitive oncology market with other companies developing antibody-drug conjugates (ADCs), immuno-oncology therapies, and prodrug biologics.
• The reported net loss and accumulated deficit are typical for clinical-stage biopharmaceutical companies that have not yet commercialized products, but the explicit 'going concern' warning indicates a more severe liquidity challenge compared to many peers who might have longer cash runways.
• The 30% workforce reduction and lease footprint reduction are aggressive cost-saving measures, which, while necessary for cash preservation, can be more pronounced than those seen in financially stable industry players.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings the outcome of which, if determined adversely, would individually or in the aggregate have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• The company has a Global Transaction Agreement with Himalaya Therapeutics SEZC (a related party where Dr. Short and his spouse are directors/officers). Under this agreement, BioAtla pays Himalaya a mid-teens percentage of upfront payments and development milestones, and a specified percentage of sales milestones and royalties received from Context under the Context License Agreement.
• Dr. Short and his spouse are managers of Inversagen, LLC and BioAtla Holdings, LLC, which have entered into various licensing arrangements with the company regarding certain CAB antibodies. These relationships create potential conflicts of interest.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises, potential loss of investment due to going concern doubt, and stock price volatility due to Nasdaq non-compliance and overall financial performance.
• Employees: Experienced a 30% workforce reduction in March 2025, indicating job insecurity and potential impact on morale.
• Customers/Patients: Continued development of product candidates offers potential future therapies, but financial instability and potential program delays could impact availability.
• Creditors/Suppliers: May face extended payment terms or reduced business if the company's financial condition deteriorates further.
• Licensors/Collaborators: The company's financial health and going concern status could impact its ability to meet obligations under existing agreements and attract new partnerships.

Next Steps

• Secure adequate additional funding through public or private equity or debt financings, or other sources, to alleviate going concern doubt.
• Continue development of product candidates, including ongoing Phase 2 clinical trials for mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and the Phase 1 clinical trial for BA3182 (CAB-EpCAM x CAB-CD3).
• Context Therapeutics expects to complete the IND filing for BA3362 (CT-202) in Q2 2026.
• Comply with Nasdaq's Minimum Stockholders Equity Requirement by December 31, 2025.
• Comply with Nasdaq's Minimum Bid Price Requirement by February 2, 2026.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial statements.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about our ability to continue as a going concern' and having less than 12 months of cash runway. Stockholders' equity has turned significantly negative, and the company is non-compliant with Nasdaq listing rules, facing potential delisting. While cost-cutting measures and a recent milestone payment are noted, they are insufficient to offset the fundamental liquidity and operational challenges. The high level of uncertainty regarding future funding, clinical trial success, and regulatory approvals, combined with the risk of significant shareholder dilution, makes the stock a high-risk investment with a strong likelihood of further value erosion.

Keywords

Biopharmaceutical, Oncology, CAB technology, Clinical trials, Antibody-drug conjugate, Mecbotamab vedotin, Ozuriftamab vedotin, Evalstotug, BA3182, Nasdaq listing, Going concern, Capital raise, Research and development, Corporate restructuring, Intellectual property, SEC filing